RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

XPOVIO

w/dexamethasone

Multiple myeloma (penta-refractory)STORM
Early Stage
Mid Stage
Late Stage
Commercial

w/bortezomib + dexamethasone

Multiple myeloma (2L+)BOSTON
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

DLBCL (R/R)SADAL
Early Stage
Mid Stage
Late Stage
Commercial

SELINEXOR
Pivotal Phase 3s

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

SELINEXOR

w/R-GDP

DLBCL (R/R)XPORT-DLBCL-030
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Endometrial Cancer (maintenance)SIENDO
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Endometrial cancer (maintenance; p53 wild-type)XPORT-EC-042
Early Stage
Mid Stage
Late Stage
Commercial

w/pomalidomide + dexamethasone

Multiple myeloma (2L+; post anti – CD38)XPORT-MM-031
Early Stage
Mid Stage
Late Stage
Commercial

w/ruxolitinib

Myelofibrosis (treatment naïve)SENTRY (XPORT-MF-034)
Early Stage
Mid Stage
Late Stage
Commercial

SELINEXOR
Phase 2s

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

SELINEXOR – Pivotal Phase 3s

monotherapy 4,5 (agreement with SOBI)

Myelofibrosis (treatment naïve)SENTRY-2 (XPORT-MF-044)
Early Stage
Mid Stage
Late Stage
Commercial

w/standard approved agents

Multiple myeloma (relapsed/refractory)STOMP
Early Stage
Mid Stage
Late Stage
Commercial

SELINEXOR

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

SELINEXOR – Phase 2s

w/R-GDP

DLBCL (R/R)XPORT-DLBCL-030
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Endometrial Cancer (maintenance)SIENDO
Early Stage
Mid Stage
Late Stage
Commercial

ELTANEXOR

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

ELTANEXOR

monotherapy

Myelodysplastic neoplasms (relapsed/refractory)KCP-8602-801
Early Stage
Mid Stage
Late Stage
Commercial
Hematologic Cancer
Solid Tumor Cancer